Abstract
Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Current Neuropharmacology
Title: Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Volume: 8 Issue: 3
Author(s): Dirk Fitzner and Mikael Simons
Affiliation:
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Abstract: Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Export Options
About this article
Cite this article as:
Fitzner Dirk and Simons Mikael, Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246218
DOI https://dx.doi.org/10.2174/157015910792246218 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling
Current Drug Targets Tactile Angle Discrimination Decreases due to Subjective Cognitive Decline in Alzheimer’s Disease
Current Alzheimer Research Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Antimicrobial and Structural Properties of Metal Ions Complexes with Thiosemicarbazide Motif and Related Heterocyclic Compounds
Current Medicinal Chemistry Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy Intracellular Protozoan Parasites of Humans: The Role of Molecular Chaperones in Development and Pathogenesis
Protein & Peptide Letters In Silico Stereo-Electronic Analysis of PMD (p-Menthane-3-8-Diol) and its Derivatives for Pharmacophore Development May Aid Discovery of Novel Insect Repellents
Current Computer-Aided Drug Design Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery
Current Drug Targets - Infectious Disorders Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Current Alzheimer Research The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued)